PARP1 INHIBITORs PARP1 inhibitors are back in the headlines this week, as Astra Zeneca’s (Cambridge, England) and Merck’s (Kenilworth, New Jersey) Lynparza posted positive Phase III results from a trial with pancreatic cancer patients—a notoriously difficult...
FOUR MOLECULAR VARIANTS EXPLAINED Hearing your doctor utter the words HER2-positive, HR-positive, triple-negative, or BRCA mutation can be devastating — even for the most resilient person. Simply put, breast cancer is a complex disease. A diagnosis can be derived...
About Biotech Primer
From startups to the Fortune 500, we train employees at companies of all sizes. We offer customized, in-house courses and open enrollment classes. Visit Biotech Primer for more information.
